FDA Historical Calendar

TickerCurrent price52 hi52 loProductIndicationPDUFA dateDecisionNotes
SNY48.8657.4243.57ToujeoType 1 and type 2 diabetesApprovedApproved Feb 26 2015
ESALY52.1552.8835.79Lenvatinib mesylate (lenvatinib)Differentiated thyroid cancer (DTC) 4/14/2015ApprovedApproved Feb 13 2015
PCYC215.93231.0982.51IMBRUVICAWaldenström’s Macroglobulinemia4/17/2015ApprovedApproved Jan 29, 2015
ZGNX1.684.711.07 Abuse deterrent formulations of Zohydro ERModerate to severe pain1/30/2015ApprovedApproved January 30 2015
RMTI10.0014.808.10Soluble Ferric PyrophosphateIron deficiency1/24/2015ApprovedApproved Jan 26 2015
NPSP0.00#N/A#N/ANatparaHypoparathyroidism1/24/2015ApprovedApproved Jan 23 2015
IPXL40.2941.3922.12IPX066Parkinson's Approved Jan 8 2015
VRTX119.43127.6959.79KALYDECOCystic fibrosis (CF) ages 6 and older who have the R117H mutation12/30/2014ApprovedApproved Dec 28 2014
ADMS17.2821.6312.02NamzaricModerate to severe dementia of the Alzheimer's type.ApprovedApproved Dec 24 2014
BCRX10.2014.627.29Peramivir INFLUENZA ACUTE 12/23/2014ApprovedApproved Dec 22 2014
ENTA35.8252.5831.22VIEKIRA PAKHCV - genotype 112/21/2014ApprovedApproved December 19 2014
ABBV60.5070.7645.50VIEKIRA PAKHCV - genotype 112/21/2014ApprovedApproved December 19 2014
CBST101.94101.9958.50Ceftolozane/ tazobactam ZERBAXAComplicated Urinary Tract Infections (cUTI) and Complicated Intra-Abdominal Infections (cIAI)12/21/2014ApprovedApproved Dec 21 2014- priority review
POZN7.339.735.96PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcers12/30/2014CRLCRL Apr 25 2014. Further CRL issued Dec 17 2014 - due to deficiencies with facility. Intends to schedule a Type A meeting with FDA to address issues
INCY85.8588.4440.30Jakafi Polycythemia Vera5/12/2014ApprovedApproved December 4 2014
AVNR16.9617.053.02AVP-825Acute migraine11/26/2014CRLCRL November 26 2014 - likely to resubmit 1H 2015
AEZS0.651.540.48Macimorelin AcetateAdult Growth Deficiency 11/5/2014CRL New trials required
PGNX6.517.843.10Subcutaneous RELISTORChronic pain9/29/2014Approved
SLXP157.20172.9886.00Subcutaneous RELISTORChronic pain9/29/2014Approved
ALIM5.238.364.58IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
PSDV4.404.943.26IluvienDiabetic macular edema9/26/2014Approved Sept 26 2014
AUXL36.4737.9217.10AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
VVUS2.616.402.41AvanafilErectile dysfunction9/20/2014ApprovedApproved 9/18/2014 - sNDA to change label allowing use 15 minutes before sexual activity.
NKTR13.0717.5310.10NaloxegolOpioid-induced constipation (OIC)9/16/2014ApprovedApproved Sept 16 2014
SLXP157.20172.9886.00Budesonide foamModerate ulcerative proctitis or proctosigmoiditis 9/15/2014Tentative approvalTentative approval granted September 15 2014 pending patent issues
HALO15.0716.256.88HYQVIASubcutaneous treatment for patients with primary immunodeficiency (PI)ApprovedApproved Sept 12 2014
OREX5.647.823.11ContraveObesity9/11/2014ApprovedApproved September 11 2014
MDVN117.53120.7254.37XTANDICancer - mCRPC who have not received chemotherapy9/17/2014ApprovedApproved Sept 10 2014
KERX12.1618.4810.85ZerenexHyperphosphatemia9/7/2014ApprovedApproved Sept 5 2014
LGND55.0780.2141.99PromactaAplastic AnemiaApproved Approved August 27 2014
MDCO28.7632.1319.92OritavancinABSSSI8/6/2014ApprovedApproved under priority review
PCYC215.93231.0982.51Ibrutinib Deletion 17pApprovedApproved July 29 2014
PCYC215.93231.0982.51Ibrutinib Cancer - Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphoma (CLL/SLL)ApprovedApproved July 29 2014
ACRX8.8613.645.22ZalvisoPost-operative pain following open abdominal surgery and hip or knee replacement surgery7/27/2014CRLCRL Jul 26 2014
EGRX34.0040.909.16RyanodexMalignant hyperthermia7/22/2014Approved
SLXP157.20172.9886.00RUCONESTHereditary angioedema (HAE)7/16/2014Approved Partnered with Dutch company Pharming
ANAC43.5044.6413.19TavaboroleOnychomycosis7/29/2014ApprovedApproved July 8 2014
SPPI6.239.275.65BelinostatCancer - Peripheral T-Cell Lymphoma8/9/2014ApprovedApproved two months early under accelerated approval program.
EGRX34.0040.909.16EP-3101 (bendamustine RTD) Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma7/6/2014Approved - tentativeTentative approval (July 2 2014) will convert to a final approval subject to patent litigation with Teva Pharmaceutical
FLML15.6519.509.30VAZCULEP (phenylephrine hydrochloride)Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia8/6/2014ApprovedApproved June 30 2014. PDUFA of August 6 was for a resubmission following CRL
NPSP0.00#N/A#N/AGATTEXShort Bowel Syndrome 7/28/2014ApprovedsNDA - seeking additions to label
MNKD6.5211.483.80AFREZZA Type 1/2 diabetes7/15/2014ApprovedApproved June 27 2014
CBST101.94101.9958.50Tedizolid phosphateAcute bacterial skin and skin structure infections (ABSSSI)6/22/2014Approved Approved June 20 2014
NAVB1.622.120.97LymphoseekHead and Neck Cancer6/16/2014ApprovedApproved Jun 13 2014
BDSI14.9918.486.71BEMA Buprenorphine/Naloxone (BNX) - BUNAVAILOpioid dependence6/7/2014ApprovedApproved June 7 2014
OMER20.8725.849.76OmidriaCataract surgery6/1/2014Approved Approved June 2 2014
TRLPF0.630.850.29Loading...PDUFA5/28/2014PDUFA date February 28 2014, extended to May 28 2014, for bioadhesive intranasal gel testosterone product (CompleoTRT)
QRXPY0.054.350.05MOXDUOModerate to severe acute pain5/25/2014CRL
DRTX0.00#N/A#N/ADalbavancinAcute bacterial skin and skin structure infections (ABSSSI)5/26/2014ApprovedApproved May 23 2014
FLML15.6519.509.30??????4/28/2014CRLCRL April 28 2014
MDCO28.7632.1319.92CangrelorReduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI).4/30/2014CRLCRL April 30 2014
POZN7.339.735.96PA32540 and PA8140Cardiovascular patients at risk for developing aspirin-associated gastric ulcers4/25/2014CRLCRL Apr 25 2014 - manufacturing deficiencies
TSX:PLBImpavidoTropical disease leishmaniasis3/19/2014ApprovedApproved Mar 19
BMY60.9264.4446.30Eliquis To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
PFE34.3234.9727.51EliquisTo Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery3/15/2014ApprovedApproved March 14 2014
ENDP85.6087.3653.62AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadism3/28/2014ApprovedApproved March 6 2014
AZN68.9082.6861.79MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
BMY60.9264.4446.30MetreleptinLipodystrophy2/27/2014ApprovedApproved Feb 25 2014
CHTPNORTHERA Neurogenic Orthostatic HypotensionApprovedApprovedApproved one day late due to snow. Acquired by Lundbeck
BMRN107.07111.8955.04Vimizim (GALNS)(MPS IVA) Morquio A Syndrome2/28/2014Approved Early approval. Was under priority review
DRRX1.051.890.68PosidurPost-operative pain relief 2/12/2014CRL
PCYC215.93231.0982.51Ibrutinib Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy2/28/2014ApprovedApproved Feb 12 2014
VNDA10.7619.258.34HETLIOZ (tasimelteon)Non-24-Hour Sleep-Wake Disorder1/31/2014Approved
VRX197.48204.66106.00Retin-A Micro (tretinoin) Gel microsphere 0.08% Acne vulgarisApprovedsNDA
AMAG49.2349.9816.49FerahemeIron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) to all adult patients with IDA who have failed or could not tolerate oral iron treatment1/21/2014CRLOriginal PDUFA date delayed
AZN68.9082.6861.79FARXIGA (dapagliflozin) tablets Adult patients with type 2 diabetesApproved
BMY60.9264.4446.30FARXIGA (dapagliflozin) tabletsAdult patients with type 2 diabetesApproved
GSK47.4256.6041.25Mekinist (trametinib) and Tafinlar (dabrafenib)Unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutationsApprovedAccelerated approval based on Phase 2 trial. Approval coningent on Phase 3 trial outcome
MRK58.5463.6252.49ISENTRESS for oral suspensionHIV-1 infected infants and childrenApproved
AZN68.9082.6861.79Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
BMY60.9264.4446.30Forxiga (dapagliflozin)Type 2 diabetes1/11/2014ApprovedApproved three days prior to PDUFA
SNY48.8657.4243.57LemtradaRelapsing forms of multiple sclerosis.CRLCRL 29/12/13
UTHR155.05164.3884.63Oral treprostinilPulmonary arterial hypertension (PAH)2/16/2014ApprovedApproved Dec 20 2013. Early approval following previous extension
THRX18.0631.8210.58UMEC/VI (62.5/25mcg and 125/25mcg doses) ANORO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)12/18/2013ApprovedApproved Dec 18 2013
JNJ102.51109.4990.75Canagliflozin and immediate-release metforminAdults with type 2 diabetesCRL
GILD103.53116.8363.50Sovaldi (Sofosbuvir)HCV6/12/2013Approved
AUXL36.4737.9217.10XIAFLEXPeyronie’s6/12/2013ApprovedApproved Dec 6 2013
PCYC215.93231.0982.51Ibrutinib versus temsirolimus - RAY (MCL3001)Cancer - relapsed or refractory MCL mantle cell lymphoma2/28/2013Approved Approved Nov 13 2013, 3 months early. Was under priority review
ZGNX1.684.711.07Zohydro ERModerate to severe painApprovedApproved Oct 25 2013. Decision was delayed by several months
AGN232.74234.68115.94JUVÉDERM VOLUMA XCAge-related volume loss in the cheek area in adults over the age of 21ApprovedApproved Oct 23 2013
ALIOF119.75129.2592.10Macitentan (Opsumit)Pulmonary arterial hypertension10/18/2013ApprovedApproved Oct 18 2013
ALIM5.238.364.58IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
PSDV4.404.943.26IluvienDiabetic macular edema10/17/2013CRLCRL Nov 2011. Second CRL Oct 17 2013. Adcom meeting Jan 27 2014
ATRS2.614.681.82OTREXUPRheumatoid arthritis (RA)10/14/2013ApprovedApproved Oct 14 2013
DCTH1.276.720.98CHEMOSAT systemCancer - unresectable metastatic ocular melanoma in the liver9/13/2013CRL CRL Sept 13 2013
CELG121.53125.4566.85ABRAXANEMetastatic pancreatic cancer9/21/2013ApprovedApproved Sep 6 2013
QRXPY0.054.350.05MOXDUOModerate to severe acute pain8/26/2013CRLCRL Aug 2013. Expects to resubmit 4Q 2013. Expects Adcom meeting
SUPN8.9911.477.09Trokendi XR SPN-538EpilepsyApprovedApproved Aug 19 2013
JNJ102.51109.4990.75SIMPONI ARIARheumatoid ArthritisApprovedApproved Jul 18 2013
MRK58.5463.6252.49Suvorexant tabletsInsomniaCRLAdcom May 22 2013. 13-3 positive vote. CRL received Jul 1 2013
GSK47.4256.6041.25Dolutegravir - ViiV HealthcareHIV8/17/2013ApprovedPDUFA Aug 12 under priority review.
JNJ102.51109.4990.75XARELTO (rivaroxaban)Stent Thrombosis in Patients with Acute Coronary SyndromeCRLCRL issued Jun 28 2013
THRX18.0631.8210.58VIBATIV (telavancin hydrochloride) for injectionHospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)ApprovedApproved Jun 21 2013
AMGN157.72173.14108.20XGEVACancer - Giant Cell Tumor Of BoneApprovedApproved 6/13/13
AVEO1.251.960.61TivozanibCancer - advanced renal cell carcinoma7/28/2013CRLNegative 1-13 vote at Adcom meeting May 2 2013.Early CRL Jun 10 2013
CELG121.53125.4566.85REVLIMIDCancer - relapsed/refractory mantle cell lymphomaApproved Approved Jun 5 2013 under priority review
FLML15.6519.509.30Bloxiverz (neostigmine methylsulfate)Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery5/31/2013ApprovedApproved Jun 3 2013
DEPO21.9523.209.85SEFELSAHot flashes5/31/2013CRLCRL May 31 2013
ENDP85.6087.3653.62AVEED (testosterone undecanoate) intramuscular injectionMen diagnosed with hypogonadismCRLCRL issued May 30 2013. Expects to respond 3Q 2013
GSK47.4256.6041.25DabrafenibCancer - melanoma6/3/2013Approved Approved May 29 2013
GSK47.4256.6041.25TrametinibCancer - melanoma6/3/2013ApprovedApproved May 29 2013
VRX197.48204.66106.00EfinaconazoleOnychomycosis5/24/2013CRLCRL May 28 2013
JNJ102.51109.4990.75SIMPONI (golimumab) ulcerative colitis (UC)ApprovedApproved May 16
THRX18.0631.8210.58BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
GSK47.4256.6041.25BREO ELLIPTAChronic Obstructive Pulmonary Disease (COPD)5/12/2013ApprovedApproved May 10 2013
BMY60.9264.4446.30SUSTIVA® (efavirenz)HIV-1ApprovedsNDA approved May 3 2013
MRK58.5463.6252.49LIPTRUZET (ezetimibe and atorvastatin)LDL CholesterolApprovedApproved May 3 2013
SHPG241.91264.98141.66Vyvanse® (lisdexamfetamine dimesylate) Children and Adolescents with ADHD5/1/2013ApprovedApproved May 1 2013
TTNP0.640.870.44ProbuphineOpioid dependence4/30/2013CRLCRL issued midnight Apr 30
RPTP9.2716.937.12DR CysteamineCystinosis4/30/2013ApprovedApproved Apr 30, 2013.
GILD103.53116.8363.50ElvitegravirHIV4/27/2013CRLCRL Apr 29 2013
GILD103.53116.8363.50CobicistatHIV4/28/2013CRLCRL Apr 29 2013
SCMP15.3816.545.80Amitiza/ LubiprostoneOpioid-induced bowel dysfunction4/24/2013ApprovedApproved Apr 23 2013
NVS102.40103.5080.64Simbrinza(TM) SuspensionGlaucomaApprovedApproved Apr 19 2013
JNJ102.51109.4990.75InvokanaType 2 diabetes3/31/2013ApprovedApproved Mar 29 2013
APPA12.99APF530Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)3/27/2013CRLCRL Mar 28 2013. Changed ticker to HRTX
UTHR155.05164.3884.63Treprostinil diolamine extended release tablets (oral treprostinil)Pulmonary arterial hypertension3/31/2013CRLCRL Mar 25, 6 days early
NAVB1.622.120.97LymphoseekLymphatic-tissue tracing agent4/30/2013Approved Approved Mar 13 2013. 7 weeks early.
JNJ102.51109.4990.75XARELTOReduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS)3/5/2013CRLCRL March 5 2013
ONXXStivargaMetastatic and/or unresectable gastrointestinal stromal tumors (GIST)2/25/2013ApprovedApproved Feb 25 2013. Acquired by Amgen.
DVAX17.6020.9012.50HEPLISAVHepatitis B2/24/2013CRLCRL Feb 25 2013. Hopes to meet with FDA by mid April to discuss CRL
IMGN7.6017.805.34KadcylaCancer - 2nd-line HER2+ Metastatic Breast Cancer2/26/2013ApprovedApproved Feb 22 2013 - under priority review
NVS102.40103.5080.64Zortress (everolimus)Prevent organ rejection in adult liver transplant patientsApprovedApproved Feb 15 2013
CELG121.53125.4566.85PomalystCancer - Multiple Myeloma2/10/2013ApprovedApproved Feb 8 2013
HEB0.240.490.21Ampligen CFS2/4/2013CRLCRL Feb 4 2012. Resubmission. More trials required. Intends to appeal
HPTX29.5532.9820.23RavictiUrea cycle disorders1/22/2013ApprovedApproved Feb 1 2013. FDA had advised company of delay
FURX0.00#N/A#N/AAlogliptinDiabetes - Type 21/27/2013Approved NDA resubmitted July 27 2012, following CRL. Approved Jan 25 2013
IPXL40.2941.3922.12IPX066Parkinson's 1/21/2013CRLCRL January 21 2013
PATHZecuity Migraine1/17/2013ApprovedApproved Jan 17 2013. Acquired by TEVA.
SNTSBudesonideUCERIS (Budesonide)Ulcerative colitis disease1/16/2013ApprovedApproved Jan 14 2013, two days early. Acquired by Salix.
AEGR27.2062.6119.10LomitapideHomozygous familial hypercholesterolemia (HoFH)1/6/2013ApprovedEarly approval Dec 24 2012
ALXA2.115.731.25Staccato loxapine (ADASUVE). Schizophrenia12/21/2012Approved
NPSP0.00#N/A#N/AGattexShort bowel syndrome or SBS12/30/2012ApprovedPDUFA date was Dec 30 2012. Early approval on Dec 21
ARIA8.139.134.90Oral ponatinibCancer - chronic myeloid leukemia, acute lymphoblastic leukemia3/27/2013ApprovedPDUFA March 27 2013. Early approval Dec 14 2012 under priority review
EXEL2.937.581.26CabozantinibCancer - Medullary thyroid 11/29/2012ApprovedApproved Nov 29 2012 under priority review
LGND55.0780.2141.99Promacta/RevoladeThrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C11/30/2012ApprovedApproved Nov 19 2012 under priority review, 11 days prior to PDUFA date
CRTXCRTX 080Hyponatremia10/29/2012CRLAdditional clinical and non-clinical information required. Acquired by Chiesi Farmaceutici S.p.A
SUPN8.9911.477.09OxtellarEpilepsy10/22/2012Approved
NAVB1.622.120.97LymphoseekLymphatic-tissue tracing agent9/10/2012CRL3rd party manufacturing deficiencies cited
MDVN117.53120.7254.37MDV3100Cancer - prostate 2nd line8/31/2012Approved Early approval decision by 3mths approx. Was under priority review
TLON0.161.830.13Marqibo2nd line adult Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)8/12/2012Approved Approved 8/9/2012
HALO15.0716.256.88HyQPrimary immunodeficiency diseaseCRL
PGNX6.517.843.10Subcutaneous RELISTORchronic pain7/27/2012CRLPrice shown is for PGNX. Partnered with SLXP
AMRN1.512.090.78Vascepa Elevated triglyceride levels7/26/2012Approved
HZNP20.5321.457.85LODOTRA (RAYOS)Rheumetoid Arthritis7/26/2012Approved
ONXXCarfilzomibMultiple myeloma7/20/2012ApprovedAcquired by Amgen.
VVUS2.616.402.41QnexaObesity7/18/2012Approved
ARNA4.517.243.26LorcaserinObesity6/27/2012Approved
QRX0.020.930.01MOXDUOModerate to severe acute pain6/26/2012CRL
RGEN25.7126.7512.04RG1068Detection of pancreatic duct abnormalities6/22/2012CRL
XNPT6.859.603.14HorizantPostherpetic Neuralgia6/9/2012Approved
ARIA8.139.134.90RidaforolimusSoft tissue or bone sarcoma6/6/2012CRL
EBS29.9730.7419.31BioThraxAnthrax Vaccine5/17/2012ApprovedApproved May 17 2012
TLON0.161.830.13MarqiboPhiladelphia chromosome-negative acute lymphoblastic leukemia 5/13/2012Extended
ALXA2.115.731.25ADASUVESchizophrenia5/3/2012CRL
PLX1.925.301.71Taliglucerase alfa Gaucher disease5/1/2012Approved
VVUS2.616.402.41AvanafilErectile dysfunction4/29/2012Approved
PGNX6.517.843.10Subcutaneous RELISTORChronic pain4/27/2012ExtendedPrice shown is for PGNX
FURX0.00#N/A#N/AAlogliptinDiabetes - Type 24/25/2012CRL
VVUS2.616.402.41QnexaObesity4/17/2012Extended
CHTPNORTHERA Neurogenic Orthostatic Hypotension3/28/2012CRLAcquired by Lundbeck
AFFY0.151.020.08PeginesatideAnemia in chronic renal failure (CRF)3/27/2012ApprovedBankrupt
MAPPLevadexMigraine3/26/2012CRLAcquired by Allergan
CRIS3.083.501.09VismodegibBasal Cell Carcinoma3/8/2012ApprovedEarly decision Jan 30,2012
NGSX0.010.010.00QutenzaNeuropathic pain associated with HIV-associated peripheral neuropathy (HIV-PN)3/7/2012CRL
DSCO1.612.770.99Surfaxin Respiratory Distress Syndrome - Severe3/6/2012Approved
ASTXDacogenAcute myeloid leukemia3/6/2012CRLAcquired by Otsuka
CBRX6.947.995.09Progesterone vaginal gelReduction of risk of preterm birth2/26/2012CRL
CORT3.314.491.69Corlux - KorlymCushing's Syndrome2/17/2012Approved
BPAXBio-T-GelMale hypogonadism2/14/2012ApprovedMerged. New ticker ANIP
ALXA2.115.731.25ADASUVESchizophrenia2/4/2012Extended 3months
AMLNBYDUREONType 2 diabetes1/28/2012ApprovedAcquired by Bristol-Myers Squibb
ALKS70.2574.9638.49BYDUREONType 2 diabetes1/28/2012Approved
PLX1.925.301.71Taliglucerase alfa Gaucher disease1/2/2012Extended 3 monthsInformed Dec 6 2011
NEOLSUBSYSCancer pain1/1/2012ApprovedNew ticker INSY
AIS2.61142.70128.00AnturolOveractive bladder12/8/2011ApprovedChanged ticker to ATRS
INCY85.8588.4440.30JakafiMyelofibrosis12/3/2011ApprovedApproved Nov 16 2011
TSPT#N/A#N/A#N/AIntermezzoInsomnia11/27/2011Approved
SPPI6.239.275.65Removal of the Bioscan Requirement for ZevalinNon-Hodgkin's lymphoma11/20/2011Approved
ALIM5.23ILUVIENDiabetic macular edema11/12/2011CRLEarly CRL. Price shown is for ALIM
IGXT0.751.090.33CPI-300Major Depressive Disorder11/10/2011Approved
PCRX114.77121.9560.30EXPARELPostsurgical pain10/28/2011Approved
SGEN36.2555.9930.05ADCETRISHodgkin lymphoma8/30/2011Approved
SGEN36.2555.9930.05ADCETRISAnaplastic large cell lymphoma8/30/2011Approved
PATHZelrixMigraine8/29/2011CRLAcquired by TEVA.
MSTX0.520.930.40ExelbineNSCLC8/9/2011CRLNew ticker MSTX. Formerly ANX
TSPT#N/A#N/A#N/AIntermezzoInsomnia7/14/2011CRL
PTIE1.906.221.61REMOXYModerate to severe pain6/23/2011CRL
FCSC4.876.302.28LavivWrinkles6/22/2011Approved
ACUR0.852.120.41OxectaPain relief6/17/2011Approved
OPTRFidaxomicinCDI - diarrhea5/30/2011Approved
SPPI6.239.275.65FUSILEVColorectal cancer4/29/2011Approved
XNPT6.859.603.14HorizantRestless Legs Syndrome4/6/2011Approved
HGSI0.00BENLYSTALupus3/10/2011Approved
PLX1.925.301.71Taliglucerase alfa Gaucher disease2/25/2011CRL
OREX5.647.823.11ContraveObesity1/31/2011CRL
DEPO21.9523.209.85GRALISEPostherpetic neuralgia - shingles1/30/2011Approved
MNKD6.5211.483.80AfrezzaInsulin1/26/2011CRLEarly CRL
CLDA#N/AViibrydMajor depressive disorder1/23/2011ApprovedAcquired by Forest Laboratories (FRX)
PSDV/ALIM#N/AILUVIENDiabetic macular edema12/29/2010CRLEarly CRL. Price shown is for ALIM
CADX0.00OFIRMEVPain and fever11/4/2010Approved
BIOD1.363.711.20VIAjectDiabetes10/30/2010CRL
AVNR16.9617.053.02NUEDEXTAPseudobulbar affect10/30/2010Approved
VVUS2.616.402.41QnexaObesity10/28/2010CRL
ALKS/AMLN#N/ABYDUREONType 2 diabetes10/22/2010CRL
ISTA0.00BROMDAYPostoperative inflammation and reduction of ocular pain10/16/2010ApprovedAcquired by Bausch + Lomb
QCOR0.0097.8047.71ActharInfantile spasms10/15/2010Approved
ALXA2.115.731.25ADASUVESchizophrenia10/11/2010CRL
JAZZ170.09183.84120.38JZP-6Fibromyalgia10/11/2010CRL
HGSIZALBINHepatitis C10/5/2010CRLAcquired by GSK
PGNX6.517.843.10RelistorOpioid-induced constipation (OIC)9/29/2010Approved
SVNTKRYSTEXXAGout9/14/2010ApprovedBankrupt
QCOR0.0097.8047.71ActharInfantile spasms6/11/2010Extended 4 months
POZN7.339.735.96VIMOVOGastric ulcers4/30/2010Approved
ITMN0.00#N/A#N/AEsbrietIdiopathic pulmonary fibrosis 4/5/2010CRL
SLXP157.20172.9886.00XIFAXANHepatic encephalopathy3/24/2010Approved
CTIC2.344.222.00PixuvriNon-Hodgkin's lymphoma3/23/2010CRL
SOMX3.005.441.29SilenorInsomnia3/19/2010Approved
APPA12.99APF530Chemotherapy-induced nausea and vomiting3/18/2010CRLChanged ticker to HRTX
SUPG0.00DacogenMyelodysplastic syndromes3/8/2010ApprovedChanged ticker to ASTX
ALKS70.25BYDUREONType 2 diabetes3/5/2010CRLPrice shown is for ALKS
CRXXExalgoModerate to severe pain in opioid tolerant patients3/2/2010ApprovedChanged ticker to ZLCS
CADXOFIRMEVPain and fever2/12/2010CRL
DDSS#N/AOleptroMajor depressive disorder2/11/2010ApprovedBankrupt
XNPT6.859.603.14HorizantRestless Legs Syndrome2/9/2010CRL
PLX1.925.301.71Taliglucerase alfa Gaucher disease2/9/2010Extended
ACOR33.8445.4528.26AMPYRAImprove walking in patients with multiple sclerosis1/22/2010Approved
MNKD6.5211.483.80AFREZZADiabetes1/16/2010CRLFDA responded 15 Mar 2010
FCSC4.876.302.28LavivWrinkles1/4/2010CRLEarly CRL
VIONOnriginAcute myeloid leukemia12/12/2009CRLBankrupt
SOMX3.005.441.29SilenorInsomnia12/4/2009CRL
SNTSZEGERIDGERD12/4/2009ApprovedAcquired by Salix.
DYAX15.1117.206.05KALBITORHereditary angioedema 12/1/2009Approved
NGSX0.010.00QutenzaPostherpetic neuralgia11/16/2009Approved
CADXOFIRMEVMild to moderate pain11/13/2009Approved
TSPT#N/A#N/A#N/AIntermezzoInsomnia11/2/2009CRL
GTXI0.802.030.41ToremifeneReduce fractures in men with prostate cancer10/30/2009CRL
SPPI6.239.275.65FUSILEVColorectal cancer10/8/2009CRL
ALTH#N/A#N/AFOLOTYNPeripheral T-cell lymphoma9/24/2009Approved
ISTABepreveAllergic conjunctivitis9/14/2009ApprovedAcquired by Bausch + Lomb
SPPI6.239.275.65ZEVALINNon-Hodgkin's Lymphoma 9/7/2009Approved
NGSX0.010.010.00QutenzaPostherpetic neuralgia8/17/2009Extended 3 months
SVNTKRYSTEXXAGout8/3/2009CRLBankrupt
DDSS#N/AOleptroMajor depressive disorder7/20/2009CRLBankrupt
ZGNX1.684.711.07SumavelMigraine7/15/2009Approved
ARDM7.45SumavelMigraine7/15/2009Approved
SPPI6.239.275.65ZEVALINNHL7/2/2009CRL
HEB0.240.490.21AmpligenChronic fatigue syndrome5/25/2009CRLCRL PR released Dec 1, 2009. PDUFA date was May 25, 2009. FDA advised only of a 1-2 week delay

About the author

Currently residing in New Zealand and employed in the education industry, Mr. A. Burden holds a M.Com in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.

2 Responses to “FDA Historical Calendar”

  1. Chirag says:

    a thousand thanks !!

Leave a Reply